MOTS-c vs SLU-PP-332

MOTS-c and SLU-PP-332 represent two divergent strategies for modulating metabolic and exercise-related pathways in research. MOTS-c, a 16-amino-acid mitochondrial-derived peptide, acts primarily through AMPK activation to influence glucose metabolism and insulin sensitivity. In contrast, SLU-PP-332 is a synthetic small molecule that directly activates estrogen-related receptors (ERRα, ERRβ, ERRγ), thereby upregulating the transcriptional program associated with aerobic exercise. Despite overlapping research interests in metabolic health, their mechanisms, evidence maturity, and translational status diverge significantly. Researchers should weigh these differences when designing studies, as MOTS-c has progressed to a modified analog in early human trials, while SLU-PP-332 remains confined to murine models with no human data available.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at the University of Southern California, it functions as a metabolic regulator primarily through AMPK activation. In preclinical mouse models, MOTS-c has been shown to prevent diet-induced obesity and insulin resistance, enhance exercise capacity—with aged mice running twice as long on treadmill tests—and mitigate age-related metabolic decline. A modified analog, CB4211, demonstrated good tolerability in a Phase 1 human trial, though no clinical trials of native MOTS-c have been completed. Key research claims include improved insulin sensitivity, exercise mimetic effects, and anti-obesity properties, all supported by in vivo rodent data.

SLU-PP-332 is a small-molecule pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ) developed at Washington University in St. Louis. By activating these transcriptional master regulators, it induces the aerobic exercise gene program, increasing oxidative muscle fiber content, mitochondrial respiration, and exercise capacity in mice without any training intervention. This mechanism is fundamentally distinct from AMPK-based approaches like AICAR, as it targets the upstream regulators of oxidative metabolism. Critically, all current data derive solely from murine studies; no human trials have been conducted. Key claims include enhanced exercise endurance without training, a shift toward oxidative muscle fiber types, and protective effects against muscular dystrophy in mouse models. Researchers should note the absence of human safety or efficacy data.

Both MOTS-c and SLU-PP-332 are investigated for metabolic health, particularly in the context of energy metabolism and exercise-related adaptations. However, their research portfolios diverge beyond this common ground. MOTS-c is additionally studied for anti-aging applications, reflecting its mitochondrial origin and effects on age-related metabolic decline. SLU-PP-332, in contrast, is more frequently explored for body composition research, given its direct influence on muscle fiber type and oxidative capacity. These distinct secondary applications may guide researchers toward one compound over the other depending on whether the focus is on longevity and glucose regulation (MOTS-c) or muscle phenotype and endurance (SLU-PP-332).

For MOTS-c, no adverse effects have been reported in preclinical animal studies, though human tolerability of the native peptide remains unknown due to the absence of completed human trials. The modified analog CB4211 showed good tolerability in a Phase 1 trial, offering some indirect safety insight. For SLU-PP-332, no human safety data exist whatsoever; all information is derived exclusively from mouse studies, where twice-daily dosing was tolerated without reported toxicity. Researchers must exercise caution with both compounds, recognizing that the translational gap from rodents to humans is substantial. The lack of human data for SLU-PP-332 is particularly critical, as small-molecule agonists can have off-target effects not apparent in murine models.